Skip to main content
Genexine, Inc. logo

Genexine, Inc. — Investor Relations & Filings

Ticker · 095700 ISIN · KR7095700001 KO Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2024-01-25 Regulatory Filings
Country KR South Korea
Listing KO 095700

About Genexine, Inc.

http://www.genexine.com/

Genexine, Inc. is a clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation biologics. The company utilizes its proprietary hyFc® platform technology to create long-acting protein therapeutics. Its pipeline is led by GX-I7, a long-acting interleukin-7 designed to amplify T-cell counts for immuno-oncology applications. Other key assets in late-stage clinical trials include GX-E4, a long-acting treatment for anemia, and GX-H9 for growth hormone deficiency. Genexine's research and development efforts primarily target oncology and rare diseases.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(에페사프리필드시린지주(GX-E4) 한국 품목허가 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the company's application for product approval (GX-E4) to the Ministry of Food and Drug Safety (MFDS). Since this is a specific regulatory disclosure of a material event (filing for drug approval) rather than a general report announcement, a financial report, or a specific category like M&A or dividend, it falls under the 'Regulatory Filings' category.
2024-01-25 Korean
[기재정정]감사보고서제출(2021사업연도)
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) for an 'Audit Report Submission' (감사보고서 제출). It details corrections to financial data (assets, liabilities, profit/loss) for the 2021 fiscal year due to a restatement of financial statements regarding put options. Since this is a formal regulatory filing submitted to the exchange to update previously disclosed financial information, it falls under the category of Regulatory Filings. FY 2021
2024-01-09 Korean
[기재정정]감사보고서제출(2022사업연도)
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the company Genexine, specifically titled 'Audit Report Submission' (감사보고서 제출). It is a correction filing (정정신고) for a previously submitted audit report, detailing specific changes in financial figures (assets, liabilities, equity, and profit/loss) due to a re-statement of financial statements regarding put options. Since this is a formal regulatory disclosure of financial audit results and corrections, it falls under the category of Audit Report / Information. FY 2022
2024-01-09 Korean
[기재정정]사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for the company Genexine (제넥신) for the 23rd fiscal year (2021.01.01 ~ 2021.12.31). It contains detailed financial statements, management discussion and analysis (MDA), business operations, and risk management disclosures. In the context of Korean corporate filings, a '사업보고서' is the equivalent of an Annual Report (10-K). FY 2021
2024-01-09 Korean
[기재정정]사업보고서 (2022.12)
Audit Report / Information Classification · 100% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Genexine, Inc. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, etc.), and notes to the financial statements. It explicitly mentions a correction (정정) to the previously filed audit report due to accounting errors regarding put options. As this is a standalone audit report and not a full annual report (10-K), it falls under the Audit Report category. FY 2022
2024-01-09 Korean
기타시장안내(연구개발 우수기업 매출액 특례적용 관련)
Regulatory Filings Classification · 100% confidence The document is a short regulatory announcement from Genexine regarding their compliance with KOSDAQ listing rules for R&D-focused companies. It does not fit into specific categories like financial reports, dividends, or M&A. As it is a general regulatory notice regarding listing status and compliance, it falls under the fallback category for regulatory announcements.
2024-01-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.